换一批A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma.
第一作者：
Pieter,Sonneveld
第一单位：
Department of Hematology, EMN/Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
作者：
Pieter,Sonneveld [1]
;
Meletios A,Dimopoulos [2]
;
Mario,Boccadoro [3]
;
Hang,Quach [4]
;
P Joy,Ho [5]
;
Meral,Beksac [6]
;
Cyrille,Hulin [7]
;
Elisabetta,Antonioli [8]
;
Xavier,Leleu [9]
;
Silvia,Mangiacavalli [10]
;
Aurore,Perrot [11]
;
Michele,Cavo [12]
;
Angelo,Belotti [13]
;
Annemiek,Broijl [1]
;
Francesca,Gay [14]
;
Roberto,Mina [14]
;
Niels W C J,van de Donk [15]
;
Eirini,Katodritou [16]
;
Fredrik,Schjesvold [17]
;
Anna Sureda,Balari [18]
;
Laura,Rosiñol [19]
;
Michel,Delforge [20]
;
Wilfried,Roeloffzen [21]
;
Tobias,Silzle [22]
;
Annette,Vangsted [23]
;
Hermann,Einsele [24]
;
Andrew,Spencer [25]
;
Roman,Hajek [26]
;
Artur,Jurczyszyn [27]
;
Sarah,Lonergan [1]
;
Tahamtan,Ahmadi [28]
;
Yanfang,Liu [29]
;
Jianping,Wang [30]
;
Diego,Vieyra [30]
;
Emilie M J,van Brummelen [31]
;
Veronique,Vanquickelberghe [32]
;
Anna,Sitthi-Amorn [30]
;
Carla J,de Boer [31]
;
Robin,Carson [30]
;
Paula,Rodriguez-Otero [33]
;
Joan,Bladé [34]
;
Philippe,Moreau [35]
作者单位：
Department of Hematology, EMN/Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
[1]
National & Kapodistrian University of Athens, Athens, Greece.
[2]
Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
[3]
University of Melbourne & St. Vincent's Hospital, Melbourne, Australia.
[4]
Institute of Haematology, Royal Prince Alfred Hospital & University of Sydney, Camperdown, NSW, Australia.
[5]
Ankara University, Ankara, Turkey.
[6]
Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France.
[7]
Department of Hematology, Careggi Hospital & University of Florence, Firenze, Italy.
[8]
University of Poitiers, CHU & Inserm 1313, Poitiers, France.
[9]
Division of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.
[10]
CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France.
[11]
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli," Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
[12]
Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy.
[13]
Division of Hematology 1, AOU Città della Salute e della Scienza di Torino, University of Torino & Department of Molecular Biotechnology & Health Sciences, University of Torino, Torino, Italy.
[14]
Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
[15]
Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece.
[16]
Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway, & KG Jebsen Center for B-cell Malignancies, University of Oslo, Oslo, Norway.
[17]
Hematology Department, Institut Català d'Oncologia - Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain.
[18]
Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain.
[19]
University of Leuven, Leuven, Belgium.
[20]
University Medical Center Groningen, Groningen, The Netherlands.
[21]
Department of Medical Oncology & Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
[22]
Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
[23]
Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
[24]
Malignant Haematology & Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia.
[25]
Department of Hematooncology, University Hospital Ostrava & Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
[26]
Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland.
[27]
Genmab US, Inc., Plainsboro, NJ, USA.
[28]
Janssen Research & Development, LLC, Beijing, China.
[29]
Janssen Research & Development, LLC, Spring House, PA, USA.
[30]
Janssen Research & Development, LLC, Leiden, The Netherlands.
[31]
Janssen Research & Development, Beerse, Belgium.
[32]
Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona, Navarra, Spain.
[33]
Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, & Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (GEM/PETHEMA), Barcelona, Spain.
[34]
Hematology Department, University Hospital Hôtel-Dieu, Nantes, France.
[35]
医学主题词
成年人(Adult);老年人(Aged);女(雌)性(Female);人类(Humans);男(雄)性(Male);中年人(Middle Aged);抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);地塞米松(Dexamethasone);多发性骨髓瘤(Multiple Myeloma);治疗结果(Treatment Outcome);随机对照试验(主题)(Randomized Controlled Trials as Topic);临床试验, Ⅱ期(主题)(Clinical Trials, Phase II as Topic)
DOI
10.1080/14796694.2024.2394323
PMID
39287147
发布时间
2025-01-31
- 浏览0
Future oncology (London, England)
Future oncology (London, England)
3043-3063页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
